featured
Distant Metastasis–Free Survival Outcomes Following Pembrolizumab vs Placebo as Adjuvant Therapy for Resected Stage IIB or IIC Melanoma
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
The Lancet Oncology
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Pembrolizumab versus placebo as adjuvant therapy in resected stage IIB or IIC melanoma (KEYNOTE-716): distant metastasis-free survival results of a multicentre, double-blind, randomised, phase 3 trial
Lancet Oncol 2022 Oct 17;[EPub Ahead of Print], GV Long, JJ Luke, MA Khattak, L de la Cruz Merino, M Del Vecchio, P Rutkowski, F Spagnolo, J Mackiewicz, V Chiarion-Sileni, JM Kirkwood, C Robert, JJ Grob, F de Galitiis, D Schadendorf, MS Carlino, P Mohr, R Dummer, JE Gershenwald, CH Yoon, XL Wu, M Fukunaga-Kalabis, C Krepler, AMM Eggermont, PA AsciertoFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.